Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The new ECO grade is made using renewable feedstock
Subscribe To Our Newsletter & Stay Updated